These authors contributed equally to the work.
Gut microbiota and non-alcoholic fatty liver disease: new insights
Article first published online: 2 MAR 2013
© 2013 The Authors Clinical Microbiology and Infection © 2013 European Society of Clinical Microbiology and Infectious Diseases
Clinical Microbiology and Infection
Volume 19, Issue 4, pages 338–348, April 2013
How to Cite
Clin Microbiol Infect 2013; 19: 338–348
- Issue published online: 18 MAR 2013
- Article first published online: 2 MAR 2013
- Accepted manuscript online: 5 JAN 2013 04:55AM EST
- Manuscript Accepted: 21 DEC 2012
- Manuscript Received: 17 NOV 2012
- hepatic steatosis;
- non alcoholic fatty liver disease;
Non-alcoholic fatty liver disease (NAFLD) is a severe liver disease that is increasing in prevalence with the worldwide epidemic of obesity and its related insulin-resistance state. A ‘two-hit’ mechanism has been proposed; however, the complete physiopathogenesis remains incompletely understood. Evidence for the role of the gut microbiota in energy storage and the subsequent development of obesity and some of its related diseases is now well established. More recently, a new role of gut microbiota has emerged in NAFLD. The gut microbiota is involved in gut permeability, low-grade inflammation and immune balance, it modulates dietary choline metabolism, regulates bile acid metabolism and produces endogenous ethanol. All of these factors are molecular mechanisms by which the microbiota can induce NAFLD or its progression toward overt non-alcoholic steatohepatitis.